A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Bim contributes to resistance to various standard and novel agents. Here we demonstrate that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and that targeting Bim by combining histone deacetylase inhibitors (HDACIs) with BH3 mimetics (eg, ABT-737) overcomes bortezomib resistance. BH3-only protein profiling revealed high Bim levels (Bim(hi)) in most MM cell lines and primary CD138(+) MM samples. Whereas short hairpin RNA Bim knockdown conferred bortezomib resistance in Bim(hi) cells, adaptive bortezomib-resistant cells displayed marked Bim downregulation. HDACI upregulated Bim and, when combined with ABT-737, which released Bim from Bcl-2/Bcl-xL, potently killed bortezomib-resistant cells. These events were correlated with Bim-associated autophagy attenuation, whereas Bim knockdown sharply increased autophagy in Bim(hi) cells. In Bim(low) cells, autophagy disruption by chloroquine (CQ) was required for HDACI/ABT-737 to induce Bim expression and lethality. CQ also further enhanced HDACI/ABT-737 lethality in bortezomib-resistant cells. Finally, HDACI failed to diminish autophagy or potentiate ABT-737-induced apoptosis in bim(-/-) mouse embryonic fibroblasts. Thus, Bim deficiency represents a novel mechanism of adaptive bortezomib resistance in MM cells, and Bim-targeting strategies combining HDACIs (which upregulate Bim) and BH3 mimetics (which unleash Bim from antiapoptotic proteins) overcomes such resistance, in part by disabling cytoprotective autophagy.

[1]  H. Harada,et al.  Paclitaxel-Induced Apoptosis Is BAK-Dependent, but BAX and BIM-Independent in Breast Tumor , 2013, PloS one.

[2]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.

[3]  Osamu Takeuchi,et al.  BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program , 2010, Science.

[4]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[5]  P. Atadja,et al.  IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. , 2010, Blood.

[6]  N. Engedal,et al.  Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells. , 2013, Blood.

[7]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[8]  DJ Klinonsky.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd Ed.) , 2016 .

[9]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[10]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[11]  A. Letai,et al.  Mitochondria: gatekeepers of response to chemotherapy. , 2013, Trends in cell biology.

[12]  J. Fueyo,et al.  Autophagy pathways in glioblastoma. , 2009, Methods in enzymology.

[13]  P. Greipp,et al.  ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells , 2007, Leukemia.

[14]  P. Atadja,et al.  Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells , 2012, Molecular Cancer Therapeutics.

[15]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[16]  N. Munshi,et al.  A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma , 2007, Oncogene.

[17]  P. Richardson,et al.  Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. , 2010, Blood.

[18]  Derek W. Yecies,et al.  Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.

[19]  R. Kurzrock,et al.  Autophagy as a target for anticancer therapy , 2011, Nature Reviews Clinical Oncology.

[20]  P. L. Bergsagel,et al.  Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma , 2013, Cell Death and Disease.

[21]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[22]  D. Rubinsztein,et al.  Bim Inhibits Autophagy by Recruiting Beclin 1 to Microtubules , 2012, Molecular cell.

[23]  P. Dent,et al.  Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. , 2002, Blood.

[24]  E. Sausville,et al.  Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. , 2005, Neoplasia.

[25]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[26]  Michael D. Schneider,et al.  Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy , 2005, Cell.

[27]  G. Berchem,et al.  Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia , 2014, Leukemia.

[28]  Dian J. Cao,et al.  Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy , 2011, Proceedings of the National Academy of Sciences.

[29]  P. Choong,et al.  Bim-targeted cancer therapy: A link between drug action and underlying molecular changes , 2009, Molecular Cancer Therapeutics.

[30]  Jerry E. Chipuk,et al.  The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. , 2011, Genes & cancer.

[31]  John L Cleveland,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes , 2008, Autophagy.

[32]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[33]  Philippe Dessen,et al.  Inhibition of Macroautophagy Triggers Apoptosis , 2005, Molecular and Cellular Biology.

[34]  N. Munshi,et al.  New Strategies in the Treatment of Multiple Myeloma , 2013, Clinical Cancer Research.

[35]  R. Bataille,et al.  The imbalance between Bim and Mcl‐1 expression controls the survival of human myeloma cells , 2004, European journal of immunology.

[36]  B. Schäfer,et al.  Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. , 2010, The Journal of clinical investigation.

[37]  R. Bataille,et al.  Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex , 2005, Oncogene.

[38]  C. Rudin,et al.  Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer , 2013, Molecular Cancer.

[39]  M. Amiot,et al.  Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes , 2013, Front. Immunol..

[40]  A. Cuervo,et al.  Integration of clearance mechanisms: the proteasome and autophagy. , 2010, Cold Spring Harbor perspectives in biology.

[41]  P. Saftig,et al.  LAMP-2: A control step for phagosome and autophagosome maturation , 2008, Autophagy.

[42]  P. Marks,et al.  Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death , 2012, Proceedings of the National Academy of Sciences.

[43]  Ivan Dikic,et al.  A role for ubiquitin in selective autophagy. , 2009, Molecular cell.

[44]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[45]  References , 1971 .

[46]  N. Mizushima,et al.  Methods in Mammalian Autophagy Research , 2010, Cell.

[47]  N. L. La Thangue,et al.  HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications , 2012, Immunology and cell biology.

[48]  S. Lonial,et al.  Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. , 2011, Blood.

[49]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[50]  M. Amiot,et al.  A pivotal role for Mcl-1 in Bortezomib-induced apoptosis , 2008, Oncogene.

[51]  R. Bataille,et al.  ABT-737 is highly effective against molecular subgroups of multiple myeloma. , 2011, Blood.

[52]  Ceri M. Wiggins,et al.  Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics , 2009, The FEBS journal.

[53]  M. Minami,et al.  Rapid Degradation of Bim by the Ubiquitin-Proteasome Pathway Mediates Short-term Ischemic Tolerance in Cultured Neurons* , 2006, Journal of Biological Chemistry.

[54]  R. Johnstone,et al.  Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. , 2009, Blood.

[55]  D. Green,et al.  The BCL-2 family reunion. , 2010, Molecular cell.

[56]  P. Marrack,et al.  Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Flavell,et al.  Multisite phosphorylation regulates Bim stability and apoptotic activity. , 2008, Molecular cell.

[58]  S. Grant,et al.  Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1 , 2009, Molecular and Cellular Biology.

[59]  Nektarios Tavernarakis,et al.  Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1 , 2007, The EMBO journal.

[60]  M. Taniwaki,et al.  Involvement of BH3-only proteins in hematologic malignancies. , 2009, Critical reviews in oncology/hematology.

[61]  T. Gilmore,et al.  The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity , 2013, PloS one.

[62]  Maike A. Laussmann,et al.  Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways , 2014, Cell Death and Disease.

[63]  H. Prince,et al.  Romidepsin for Cutaneous T-cell Lymphoma , 2012, Clinical Cancer Research.

[64]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[65]  John Calvin Reed.  Priming Cancer Cells for Death , 2011, Science.

[66]  R. Bataille,et al.  The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma , 2009, British journal of haematology.

[67]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.

[68]  K. Kirkegaard,et al.  Subversion of Cellular Autophagosomal Machinery by RNA Viruses , 2005, PLoS biology.

[69]  G. Kroemer,et al.  Bcl-2 family members: dual regulators of apoptosis and autophagy. , 2008, Autophagy.